Xeris Pharmaceuticals, which is developing a novel formulation of an injectable hypoglycemia treatment, raised $86 million by offering 5.7 million shares at $15, the midpoint of the $14 to $16 range. It had previously filed to offer 5.0 million shares. Xeris Pharmaceuticals plans to list on the Nasdaq under the symbol XERS. Jefferies, Leerink Partners and RBC Capital Markets acted as lead managers on the deal.
